Grier A. Wallace - Sterling MA, US Eric C. Breinlinger - Charlton MA, US Kevin P. Cusack - Holden MA, US Thomas D. Gordon - Medway MA, US Adrian D. Hobson - Shrewsbury MA, US Martin E. Hayes - Lowell MA, US Graham K. Ansell - Millbury MA, US Pintipa Grongsaard - Shrewsbury MA, US
The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.
Gregory Roth - Woodstock CT, US Grier Wallace - Sterling MA, US Dawn George - Charlton MA, US Pintipa Grongsaard - Shrewsbury MA, US Martin Hayes - Lowell MA, US Eric Breinlinger - Charlton MA, US
International Classification:
A61K 31/4184 C07D 235/30
US Classification:
514388000, 548307400
Abstract:
Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
Eric C. Breinlinger - Charlton MA, US Kevin P. Cusack - Holden MA, US Adrian D. Hobson - Shrewsbury MA, US Bin Li - Ashland MA, US Thomas D. Gordon - Medway MA, US Robert H. Stoffel - Harvard MA, US Grier A. Wallace - Sterling MA, US Pintipa Grongsaard - Shrewsbury MA, US Lu Wang - Northborough MA, US Lu Wang - Worcester MA, US
Disclosed herein are novel compounds of Formula (I),wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases as well as proliferative disorders such as cancer.
Kevin P. Cusack - Holden MA, US Eric C. Breinlinger - Charlton MA, US Robert H. Stoffel - Harvard MA, US Kevin R. Woller - Anitoch IL, US Adrian D. Hobson - Shrewsbury MA, US Pintipa Grongsaard - Whippany NJ, US
Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.
Adrian D. Hobson - Shrewsbury MA, US Kevin P. Cusack - Holden MA, US Eric C. Breinlinger - Charlton MA, US Graham K. Ansell - Millbury MA, US Robert H. Stoffel - Harvard MA, US Kevin R. Woller - Antioch IL, US Pintipa Grongsaard - Whippany NJ, US
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
A61K 31/4245 C07D 271/06
US Classification:
514364, 548131
Abstract:
Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.